# A Study to Compare Efficacy and Safety of Nanogen's Darbepoetin Alfa With Aranesp® (Amgen) in the Treatment of Anemia in Chronic Kidney Disease Patients on Dialysis (CKD)

> **NCT05585645** · PHASE3 · COMPLETED · sponsor: **Nanogen Pharmaceutical Biotechnology Joint Stock Company** · enrollment: 214 (actual)

## Conditions studied

- Anemia
- Chronic Kidney Disease Requiring Chronic Dialysis

## Interventions

- **BIOLOGICAL:** Stimus (NNG-DEPO)

## Key facts

- **NCT ID:** NCT05585645
- **Lead sponsor:** Nanogen Pharmaceutical Biotechnology Joint Stock Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-08-08
- **Primary completion:** 2022-11-23
- **Final completion:** 2022-11-23
- **Target enrollment:** 214 (ACTUAL)
- **Last updated:** 2025-03-27

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05585645

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05585645, "A Study to Compare Efficacy and Safety of Nanogen's Darbepoetin Alfa With Aranesp® (Amgen) in the Treatment of Anemia in Chronic Kidney Disease Patients on Dialysis (CKD)". Retrieved via MORVS 2026-10-19 from https://api.morvs.ai/clinical/NCT05585645. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*